An independent guide for Australians
Retatrutide: the triple-action breakthrough coming to Australia.
Developed by Eli Lilly, Retatrutide is the first medication to target three metabolic receptors at once — delivering weight loss in clinical trials previously only seen with bariatric surgery. Here is what every Australian should know.
Latest — TRIUMPH-1 · The Lancet
28.3% mean weight loss at 80 weeks on the 12 mg dose.
See the trial results28.3%
average body weight lost in the landmark Phase 3 trial
3
hormone receptors targeted at once — a world first
70.3 lbs
average weight lost on the 12 mg dose over 80 weeks
5,800+
participants enrolled across the TRIUMPH program
Retatrutide: 28.3% mean weight loss in Phase 3, a triple hormone agonist targeting GLP-1, GIP and glucagon, published in The Lancet, with TGA review expected in 2027.
What is Retatrutide?
One weekly injection. Three receptors. Nothing else like it.
It lowers appetite, improves insulin response and lifts energy expenditure — the first medication ever to do all three at once.
Retatrutide is a first-in-class, once-weekly injectable known as a triple hormone receptor agonist. Nicknamed “Triple G” by the media, it simultaneously activates three of the body’s key metabolic receptors — an approach no approved weight-loss medication has taken before.
Learn how Retatrutide worksRetatrutide
one molecule
Appetite
Reduces appetite and slows digestion, helping you feel fuller for longer — the pathway proven by semaglutide.
TRIUMPH-1 · 80 weeks
Average body weight lost by dose
45.3% of participants on 12 mg lost 30% or more of their body weight — a level previously only associated with bariatric surgery.
The science
Trial results that have stunned researchers.
Across Eli Lilly’s Phase 3 TRIUMPH program, Retatrutide has delivered the largest weight reductions ever recorded for a medication — while also improving blood sugar, knee pain, sleep apnoea and cardiovascular risk markers.
- 65.3% of participants on 12 mg no longer met the clinical definition of obesity
- 90% of type 2 diabetes trial participants reached the ADA blood-sugar target
- 60.6% reduction in sleep apnoea severity in the TRIUMPH-1 basket study
The road to Australia
From the lab to the TGA — where things stand today.
2023
Phase 2, New England Journal of Medicine
24.2% average weight loss at 48 weeks — the strongest Phase 2 result ever recorded for a weight-loss medication, and the moment retatrutide became the most watched molecule in metabolic medicine.
Why it matters here
Australia is facing an obesity crisis.
Obesity is now Australia’s number one modifiable risk factor for disease, overtaking tobacco. It drives over 200 downstream diseases — from type 2 diabetes and heart disease to sleep apnoea and certain cancers.
66.8%
of Australian adults are overweight or obese
32%
of Australian adults are classified as obese
19,000
Australian deaths in 2024 attributable to overweight and obesity
8.3%
of Australia's total burden of disease is due to obesity
Stay informed
Be first to know.
When it reaches Australia.
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
- The latest clinical trial results and news from Eli Lilly
- Updates on TGA regulatory progress in Australia
- How and where to access Retatrutide when it becomes available
- Occasional information from retatrutide.net.au and our affiliated partners
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.